Liver Fibrosis Quantified by Image Morphometry Predicts Clinical Outcomes in Patients with Non-alcoholic Fatty Liver Disease

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2023 Jun 26

PMID 37358741

Authors

Zhengyi Wang

Gary P Jeffrey

Yi Huang

Bastiaan De Boer

George Garas

Michael Wallace

Luis Bertot

Leon A Adams

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the accuracy of semi-automated quantification of collagen proportionate area (CPA) as an objective new method for predicting clinical outcomes.

Method: Liver biopsies from patients with NAFLD underwent computerized image morphometry of Sirius Red staining with CPA quantification performed by ImageScope. Clinical outcomes, including total mortality, LRD, and combined liver outcomes (liver decompensation, HCC, or LRD), were determined by medical records and population-based data-linkage. The accuracy of CPA for predicting outcomes was compared with non-invasive fibrosis tests (Hepascore, FIB-4, APRI).

Results: A total of 295 patients (mean age 50 years) were followed for a median (range) of 9 (0.2-25) years totalling 3253 person-years. Patients with CPA ≥ 10% had significantly higher risks for total death [hazard ratio (HR): 5.0 (1.9-13.2)], LRD [19.0 (2.0-182.0)], and combined liver outcomes [15.6 (3.1-78.6)]. CPA and pathologist fibrosis staging (FS) showed similar accuracy (AUROC) for the prediction of total death (0.68 vs. 0.70), LRD (0.72 vs. 0.77) and combined liver outcomes (0.75 vs. 0.78). Non-invasive serum markers Hepascore, APRI, and FIB-4 reached higher AUROC; however, they were not statistically significant compared to that of CPA except for Hepascore in predicting total mortality (0.86 vs. 0.68, p = 0.009).

Conclusion: Liver fibrosis quantified by CPA analysis was significantly associated with clinical outcomes including total mortality, LRD, and HCC. CPA achieved similar accuracy in predicting outcomes compared to pathologist fibrosis staging and non-invasive serum markers.

Citing Articles

Role of artificial intelligence in staging and assessing of treatment response in MASH patients.

Akpinar R, Panzeri D, De Carlo C, Belsito V, Durante B, Chirico G Front Med (Lausanne). 2024; 11:1480866.

PMID: 39497843 PMC: 11532183. DOI: 10.3389/fmed.2024.1480866.

References

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Ng C, Lim W, Lim G, Tan D, Syn N, Muthiah M . Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022; 21(4):931-939.e5. PMC: 10792524. DOI: 10.1016/j.cgh.2022.04.014. View

Huang Y, Joseph J, de Boer W, Cheng W, Adams L, MacQuillan G . Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. Clin Gastroenterol Hepatol. 2019; 18(2):496-504.e3. DOI: 10.1016/j.cgh.2019.07.013. View

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

Angulo P, Hui J, Marchesini G, Bugianesi E, George J, Farrell G . The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4):846-54. DOI: 10.1002/hep.21496. View

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

Bedossa P . Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014; 60(2):565-75. DOI: 10.1002/hep.27173. View

PUCHTLER H, Isler H . The effect of phosphomolybdic acid on the stainability of connective tissues by various dyes. J Histochem Cytochem. 1958; 6(4):265-70. DOI: 10.1177/6.4.265. View

Rojkind M . A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem. 1985; 33(8):737-43. DOI: 10.1177/33.8.2410480. View

10.

Regev A, Berho M, Jeffers L, Milikowski C, Molina E, Pyrsopoulos N . Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97(10):2614-8. DOI: 10.1111/j.1572-0241.2002.06038.x. View

11.

Manousou P, Burroughs A, Tsochatzis E, Sochatzis E, Isgro G, Hall A . Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J Hepatol. 2012; 58(5):962-8. DOI: 10.1016/j.jhep.2012.12.016. View

12.

Huang Y, de Boer W, Adams L, MacQuillan G, Bulsara M, Jeffrey G . Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome. J Hepatol. 2014; 61(1):22-7. DOI: 10.1016/j.jhep.2014.02.031. View

13.

Huang Y, de Boer W, Adams L, MacQuillan G, Rossi E, Rigby P . Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int. 2013; 33(8):1249-56. DOI: 10.1111/liv.12184. View

14.

Wai C, Greenson J, Fontana R, Kalbfleisch J, Marrero J, Conjeevaram H . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2):518-26. DOI: 10.1053/jhep.2003.50346. View

15.

Adams L, Bulsara M, Rossi E, DeBoer B, Speers D, George J . Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005; 51(10):1867-73. DOI: 10.1373/clinchem.2005.048389. View

16.

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

17.

Hansen M, Kurinczuk J, Bower C, Webb S . The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med. 2002; 346(10):725-30. DOI: 10.1056/NEJMoa010035. View

18.

Freemantle C, Read A, de Klerk N, McAullay D, Anderson I, Stanley F . Patterns, trends, and increasing disparities in mortality for Aboriginal and non-Aboriginal infants born in Western Australia, 1980-2001: population database study. Lancet. 2006; 367(9524):1758-66. DOI: 10.1016/S0140-6736(06)68771-0. View

19.

Manousou P, Dhillon A, Isgro G, Calvaruso V, Luong T, Tsochatzis E . Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl. 2011; 17(2):178-88. DOI: 10.1002/lt.22209. View

20.

Saffioti F, Hall A, de Krijger M, Verheij J, Hubscher S, Maurice J . Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis. Liver Int. 2021; 41(11):2681-2692. DOI: 10.1111/liv.14979. View